Home
overview


Do you deal with drug pricing and reimbursement in North America or work in health economics or outcomes research? Do you want to hear about the latest trends in P&R and what the future holds?

SMi’s 4th Annual conference on Pharmaceutical Pricing and Reimbursement in North America will arm you with all the tools and up-to-date knowledge you need to successfully manage this. This conference will bring together top pharmaceutical companies and government agencies discussing significant changes in pricing and reimbursement controls, and their visions for future developments.



Key benefits of attending:

  • Discover the latest updates on Medicare and Medicaid; and how the rest of North America is shaping up
  • Acquire knowledge on the best practises to optimise pricing within your business to ensure you remain profitable
  • Assess how health economics and outcomes research can be used to forecast future pricing trends
  • Gain an insight into the views of payers, patients and insurance companies
  • Examine how the general elections will affect pricing



Hear contributions from leading experts such as:

  • Celestina Arrigo, Director, Global Health Outcomes, UCB Pharma SA
  • Donald Zowader, Manager, Government Affairs, Takeda Pharmaceuticals
  • W. Neil Palmer, Vice President, RTI Health Solutions
  • Jorge Mestre-Ferrandiz, Senior Economist, Office of Health Economics
  • Sarah Pitluck, Principal Analyst, Genentech
  • Veronique Toully, Director, Global Pricing Reimbursement and Access, UCB Group
  • Philip Jacobs, Director, Health Economics, Institute of Health Economics
  • Arto Ohinmaa, Professor, School of Public Health, University of Alberta
  • Leah Amir, Executive Director and President of VantageView, Institute for Quality Resource Management
  • Gary Johnson, Managing Director, Inpharmation
  • Pamela Santoni, Senior Principal, IMS Health
  • George Wyatt, Managing Director, Wyatt Health Management
  • Gustav Ando, Project Manager, Global Insight
  • David W. Miller, Former Vice President and Site Head, Elan Pharma Ltd. and President, Miller Pharma Consulting
  • Brian Lovatt, Managing Director & Chief Executive, Vision Healthcare Research



This conference is aimed at:

A Vice President, Director or Manager from:
  • Pricing
  • Reimbursement & Access            
  • Business development                 
  • Strategy analysts
  • Purchasing
  • Economic affairs
  • Health economics
  • Outcomes research
  • Pharmaceutical policy
  • Corporate / Regulatory / Government affairs 

As well as experts from the following institutions:
  • Health Care   
  • Hospitals / Pharmacies   
  • Pricing/ Strategic Consultancies
  • Academia


Last years’ delegates included:
  • Pfizer   
  • AstraZeneca Pharmaceuticals 
  • Novartis 
  • GlaxoSmithKline 
  • Roche  
  • UCB Group
  • Takeda Pharmaceuticals
  • Merck Lipha S A
  • Bioniche Life Sciences Inc.
  • Santhera Pharmaceuticals AG


For Speaking opportunities please contact Mamta Patel at mpatel@smi-online.co.uk
For Sponsorship opportunities please contact Alia Malick at amalick@smi-online.co.uk

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

W. Neil Palmer

W. Neil Palmer, Vice President, RTI Health Solutions

9:10 CURRENT TRENDS IN PRICING AND REIMBURSEMENT IN NORTH AMERICA

  • Examining the challenges facing pharmaceutical companies today
  • Important factors to consider when determining the optimal price of your products
  • Most common pitfalls in Pharmaceutical pricing
  • Strategies to effectively price products
  • Leah Amir

    Leah Amir, Executive Director and President of VantageView, Institute for Quality Resource Management

    9:50 MEDICARE - POLITICS AND MONEY

    Brian Lovatt

    Brian Lovatt, Managing Director & Chief Executive, Vision International Healthcare

  • Current status
  • Presidential positions
  • Amendments to Part B
  • The impact of Part D on pharmaceutical prices
  • Is price referencing possible?
  • 10:30 Morning Coffee

    11:00 THE IMPACT OF MEDICARE COVERAGE AND PAYMENT ON HIGH COST DRUGS AND BIOLOGICS

    Sarah Pitluck

    Sarah Pitluck, Group Manager, Government Affairs, Genentech

  • Review the Medicare coverage and payment processes used by the Centers for Medicare & Medicaid Services (CMS) for physician-administered drugs and biologics
  • Understand how the reimbursement process impacts patient access to new, often costly therapies
  • Discuss recent developments by CMS to both coverage and payment and how this impacts patient access
  • Compare the process for physician-administered drugs and biologics to oral, self-administered products
  • Provide case study examples for specific products
  • 11:40 MEDICAID COVERAGE

    Donald Zowader

    Donald Zowader, Manager, Government Affairs, Takeda Pharmaceuticals

  • Who is eligible for Medicaid coverage? What does it cover?
  • Changes and developments
  • AMP/Brands/Generics
  • Medicaid Managed Care
  • Fee for the service
  • Preferred Drug Lists and Drug Purchasing Pools
  • 12:20 Networking Lunch

    13:50 CANADIAN GUIDELINES

    Philip Jacobs

    Philip Jacobs, Director, Health Economics, Institute of Health Economics

  • How is the healthcare system structured?
  • Clarifying the Canadian reimbursement and decision-making process
  • Provincial formulary price management
  • Patents, PMPRB and price regulation
  • 14:30 COMMON DRUG REVIEW

    George Wyatt

    George Wyatt, Managing Director, Wyatt Health Management

  • Understanding the effect of the Common Drug Review on public access
  • Public reimbursement after a Common Drug Review recommendation
  • Private drug plan reimbursement in Canada
  • Will Canada adopt a National Pharmaceutical Strategy?
  • New initiatives in pharmaceutical reimbursement
  • 15:10 Afternoon Tea

    15:40 THE GENERAL ELECTION

    Gustav Ando

    Gustav Ando, Project Manager , Global Insight

  • Scenarios of the U.S. election and their tangible effects for the healthcare industry
  • Where is P&R going in the U.S.: the Republican versus Democrat Vision?
  • Will the credit crunch play a role on pharma?
  • 16:20 A GLOBAL PERSPECTIVE

    Jorge Mestre-Ferrandiz

    Jorge Mestre-Ferrandiz, Senior Economist, Office Of Health Economics

  • European P&R policies: what are the key trends?
  • Europe vs. US: What are the main similarities and differences?
  • What EU policies, if any, are likely to have an impact in the US?
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Donald Zowader

    Donald Zowader, Manager, Government Affairs, Takeda Pharmaceuticals

    9:10 CLINICAL STUDIES

    Pamela Santoni

    Pamela Santoni, Senior Principal, IMS Health

  • The necessity to identify the payers requirements early in the development process
  • Incorporating health economic data into clinical studies to support reimbursement negotiations
  • Clinical and regulatory issues in developing orphan drugs
  • Balancing profitability with social responsibility
  • Implications of accessing hospital markets
  • 9:50 ONCOLOGY PRICING

    Gary Johnson

    Gary Johnson, Managing Director, Inpharmation

  • The key challenges
  • How to appropriately price cancer drugs
  • Controlling expenditure
  • How to pay for cancer treatments in the long-term
  • 10:30 Morning Coffee

    11:00 OUTCOMES RESEARCH

    Celestina Arrigo

    Celestina Arrigo, Director, Global Health Outcomes, UCB Pharma

  • How comparative effectiveness will affect future pricing?
  • What are the main decision criteria to support a specific medicinal product?
  • Examining the difficulties of post-marketing surveillance studies
  • The methods available to measure patients ‘quality of life’
  • What can industry learn from real-life experiences?
  • 11:40 USING MODELLING TO PREDICT FUTURE TRENDS

    Arto Ohinmaa

    Arto Ohinmaa, Professor, School of Public Health, University of Alberta

  • The context: secondary prevention in newly diagnosed diabetes
  • Current issues in provincial drug coverage
  • The applicability of health economic modelling
  • Understanding how health economic models work
  • What data is needed?
  • Choosing the best model 
  • Implications for other jurisdictions: transferability of results
  • 12:20 Networking Lunch

    13:50 PRICE REFERENCING

    Veronique Toully

    Veronique Toully, Vice President, Global Pricing Reimbursement and Access, UCB

  • Emerging trends for internal and external price referencing
  • Impact of international price referencing
  • How internal price referencing influences access and formulary placement in the US
  • Optimizing global pricing strategy through value-based approach
  • Combine value-based approach, external and internal price referencing to optimize access
  • 14:30 PARALLEL TRADE

    W. Neil Palmer

    W. Neil Palmer, Vice President, RTI Health Solutions

  • What are the key drivers?
  • Trends in Internet pharmacy sales to the US from Canada
  • Prospects for US legislation to allow importation
  • Does parallel trade facilitate or prevent counterfeit products?
  • Outlook for parallel trade in North America
  • 15:10 Afternoon Tea

    15:40 SECURING PRICING AND REIMBURSEMENT IN THE GLOBAL MARKETPLACE

    David W. Miller

    David W. Miller, President, Miller Pharma Consulting

  • The local P&R requirements that drive a global program
  • Designing a global program that meets local P&R needs
  • Data sources to support P&R
  • Packaging and delivering global information to secure local P&R
  • 16:20 PANEL DEBATE: THE FUTURE - CHANGING FACE AND PACE

  • Are countries prepared to pay higher prices for new innovative medicines?
  • Examining different strategies to handle the need for high demand-low profit drugs
  • Lessons learnt and plans for the future
  • Can we achieve pricing globalisation?
  • W. Neil Palmer

    W. Neil Palmer, Vice President, RTI Health Solutions

    Donald Zowader

    Donald Zowader, Manager, Government Affairs, Takeda Pharmaceuticals

    Arto Ohinmaa

    Arto Ohinmaa, Professor, School of Public Health, University of Alberta

    17:00 Chairman’s Closing Remarks and Close of Conference

    +

    Workshops

    Predicting the US pricing environment in 10 years time
    Workshop

    Predicting the US pricing environment in 10 years time

    The Hatton, at etc. venues
    9th April 2008
    London, United Kingdom

    Maximising P&R strategies and value concepts in oncology
    Workshop

    Maximising P&R strategies and value concepts in oncology

    The Hatton, at etc. venues
    9th April 2008
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.